Anti‐PD‐1/PD‐L1 therapy augments lenvatinib's efficacy by favorably altering the immune microenvironment of murine anaplastic thyroid cancer
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Patients with anaplastic thyroid cancer (ATC) have an extremely poor prognosis despite multimodal therapy with surgery and chemoradiation. Lenvatinib, a multi‐targeted tyrosine kinase inhibitor, as well as checkpoint inhibitors targeting the programmed cell death pathway, have proven effective in some patients with advanced thyroid cancer. Combination of these therapies is a potential means to boost effectiveness and minimize treatment resistance in ATC. We utilized our novel immunocompetent murine model of orthotopic ATC to demonstrate that lenvatinib led to significant tumor shrinkage and increased survival, while combination therapy led to dramatic improvements in both. Lenvatinib monotherapy increased tumor‐infiltrating macrophages, CD8+ T‐cells, regulatory T‐cells, and most notably, polymorphonuclear myeloid derived suppressor cells (PMN‐MDSCs). While both combination therapies led to further increases in CD8+ T‐cells, only the lenvatinib and anti‐PD‐1 combination decreased PMN‐MDSCs. PMN‐MDSC expansion was also seen in the blood of mice and one patient receiving lenvatinib therapy for ATC. RNA‐Seq of the ATC cell line used in our mouse model demonstrated that lenvatinib has multifaceted effects on angiogenesis, response to hypoxia, the epithelial‐to‐mesenchymal transition, and on multiple pathways implicated in inflammation and host immunity. Combination of lenvatinib with anti‐Gr‐1 antibody ameliorated lenvatinib's expansion of MDSCs and significantly improved lenvatinib's anti‐tumor effect. These data suggest that MDSCs play a negative role in ATC's response to lenvatinib and support future study of their role as a potential biomarker and treatment target.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Near-optimal probabilistic RNA-seq quantification
Bray, N. L., Pimentel, H., Melsted, P., & Pachter, L. (2016) · Nature Biotechnology · doi:10.1038/nbt.3519 · Cited by 9,723 · cited 1×
“1, Pasadena, CA) using the GRCm38 mouse genome for indexing.(22,23) Quantified transcripts were collapsed into gene counts to be used for differential expression analysis.”
MethodInnate or adaptive immunity? The example of natural killer cells
Vivier, E., Raulet, D. H., Moretta, A., Caligiuri, M. A., Zitvogel, L., Lanier, L. L., Yokoyama, W. M., & Ugolini, S. (2011) · Science · doi:10.1126/science.1198687 · Cited by 2,824
Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards
Bronte, V., Brandau, S., Chen, S.-H., Colombo, M. P., Frey, A. B., Greten, T. F., Mandruzzato, S., Murray, P. J., Ochoa, A., Ostrand-Rosenberg, S., et al. (2016) · Nature Communications · doi:10.1038/ncomms12150 · Cited by 2,751
Alternative Activation of Macrophages: An Immunologic Functional Perspective
Martinez, F. O., Helming, L., & Gordon, S. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132532 · Cited by 2,745 · cited 10×
“MDSCs are a heterogenous population of CD11b+ immature myeloid cells with immunosuppressive activity, and are organized into early (poorly defined in mice), polymorphonuclear (PMN-MDSC), and mononuclear (M-MDSC) subsets.32 Since CD11b is a marker of myeloid and NK-cells, Ly6C and Ly6G were utilized to further focus on…”
BackgroundInfluentialDetermination of subcutaneous tumor size in athymic (nude) mice
Tomayko, M. M., & Reynolds, C. P. (1989) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00300234 · Cited by 1,830 · cited 1×
“The formula (π/6) X length X width X height was used to determine tumor volume.(26) The experiment was repeated twice (total n = 108) and representative results are shown.”
MethodVEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors
Voron, T., Colussi, O., Marcheteau, E., Pernot, S., Nizard, M., Pointet, A.-L., Latreche, S., Bergaya, S., Benhamouda, N., Tanchot, C., et al. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20140559 · Cited by 1,179 · cited 1×
“Crosstalk between these complex microenvironmental pathways has been increasingly recognized; common driver alterations in the MAPK and PI3K pathways have been shown to increase programs of angiogenesis and cell proliferation/ survival, and increased VEGF secretion by both thyroid cancer cells and tumor-infiltrating m…”
BackgroundVascular Normalization as an Emerging Strategy to Enhance Cancer Immunotherapy
Huang, Y., Goel, S., Duda, D. G., Fukumura, D., & Jain, R. K. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4354 · Cited by 669 · cited 1×
“Although anti-angiogenic therapies have fallen out of favor in cancer as monotherapies, mounting evidence supports that these agents may normalize rather than antagonize new vessel formation, improve hypoxia, and even boost the effectiveness of other drugs, including immunotherapies.(15) Neutralizing monoclonal antibo…”
BackgroundAken, B. L., Achuthan, P., Akanni, W., Amode, M. R., Bernsdorff, F., Bhai, J., Billis, K., Carvalho-Silva, D., Cummins, C., Clapham, P., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw1104 · Cited by 512 · cited 1×
“1, Pasadena, CA) using the GRCm38 mouse genome for indexing.(22,23) Quantified transcripts were collapsed into gene counts to be used for differential expression analysis.”
MethodOstrand-Rosenberg, S., & Fenselau, C. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701019 · Cited by 509 · cited 1×
“Therefore, the increase in MDSCs with lenvatinib is paradoxical; receptors targeted by lenvatinib such as VEGFR, c-kit, PDGFR, FGFR, and further downstream, STAT3 and STAT-5, have all been implicated in MDSC accumulation and/or MDSC immunosuppressive function.(43) The mechanism of lenvatinib’s expansion of MDSCs remai…”
Background
Cited by
Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions
Chen, Z., Han, F., Du, Y., Shi, H., & Zhou, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01332-8 · Cited by 1,612
New Therapies for Advanced Thyroid Cancer
Laha, D., Nilubol, N., & Boufraqech, M. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00082 · Cited by 261
Dierks, C., Seufert, J., Aumann, K., Ruf, J., Klein, C., Kiefer, S., Rassner, M., Boerries, M., Zielke, A., la Rosee, P., et al. (2021) · Thyroid · doi:10.1089/thy.2020.0322 · Cited by 254
Zhang, P., Guan, H., Yuan, S., Cheng, H., Zheng, J., Zhang, Z., Liu, Y., Yu, Y., Meng, Z., Zheng, X., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29000-5 · Cited by 86
Maniakas, A., Zafereo, M., & Cabanillas, M. E. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2021.11.020 · Cited by 80
Metadata
- Authors
- Gunda, V., Gigliotti, B., Ashry, T., Ndishabandi, D., McCarthy, M., Zhou, Z., Amin, S., Lee, K. E., Stork, T., Wirth, L., Freeman, G. J., Alessandrini, A., & Parangi, S.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2019-01-24
- Volume
- 144
- Issue
- 9
- Pages
- 2266-2278
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2902083233
- Cited by
- 111
- References
- 12
- FWCI
- 6.99
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.